To include your compound in the COVID-19 Resource Center, submit it here.

Jilted for someone younger; Hillary's investments

Jilted for someone younger

Biopharmaceutical CEOs worried that institutional investors will never again hunger to have biotech stocks in their portfolios can take some indirect comfort from the experience of Accel Partners in raising its new venture fund.

But it's the kind of comfort that can best be described as "cold," since those same institutions aren't anywhere near ready to resume their support of publicly held companies.

Accel started out to raise $125 million and ended up finding $135 million, of which about one-third will be

Read the full 847 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE